scholarly journals Neuropathy experienced by colorectal cancer patients receiving oxaliplatin: A qualitative study to validate the Functional Assessment of Cancer Therapy/Gynecologic Oncology Group-Neurotoxicity scale

2020 ◽  
Vol 12 (2) ◽  
pp. 205-218 ◽  
Author(s):  
Karen Kaiser ◽  
Madison Lyleroehr ◽  
Sara Shaunfield ◽  
Leilani Lacson ◽  
Maria Corona ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Cancer Therapy ◽  
Qualitative Study ◽  
Cancer Patients ◽  
Functional Assessment ◽  
Gynecologic Oncology ◽  
Gynecologic Oncology Group ◽  
Oncology Group ◽  
Colorectal Cancer Patients

scholarly journals Randomized Trial of Intravenous Versus Intraperitoneal Chemotherapy Plus Bevacizumab in Advanced Ovarian Carcinoma: An NRG Oncology/Gynecologic Oncology Group Study

2019 ◽  
Vol 37 (16) ◽  
pp. 1380-1390 ◽  
Author(s):  
Joan L. Walker ◽  
Mark F. Brady ◽  
Lari Wenzel ◽  
Gini F. Fleming ◽  
Helen Q. Huang ◽  
...  
Keyword(s):  
Overall Survival ◽  
Cancer Therapy ◽  
Functional Assessment ◽  
Median Overall Survival ◽  
Residual Disease ◽  
Gynecologic Oncology ◽  
Area Under The Curve ◽  
Stage Ii ◽  
Gynecologic Oncology Group ◽  
Oncology Group

PURPOSE To evaluate the impact of two different intraperitoneal (IP) chemotherapy regimens on progression-free survival (PFS) among women with newly diagnosed advanced ovarian carcinoma. METHODS Eligible patients were randomly assigned to six cycles of IV paclitaxel 80 mg/m2 once per week with intravenous (IV) carboplatin area under the curve 6 (IV carboplatin) versus IV paclitaxel 80 mg/m2 once per week with IP carboplatin area under the curve 6 (IP carboplatin) versus once every 3 weeks IV paclitaxel 135 mg/m2 over 3 hours day 1, IP cisplatin 75 mg/m2 day 2, and IP paclitaxel 60 mg/m2 day 8 (IP cisplatin). All participants received bevacizumab 15 mg/kg IV every 3 weeks in cycles 2 to 22. RESULTS A total of 1,560 participants were enrolled and had 84.8 months of follow-up. The median PFS duration was 24.9 months in the IV carboplatin arm, 27.4 months in the IP carboplatin arm, and 26.2 months in the IP cisplatin arm. For the subgroup of 1,380 patients with stage II/III and residual disease of 1 cm or less, median PFS was 26.9 (IV-carboplatin), 28.7 (IP-carboplatin), and 27.8 months (IP cisplatin), respectively. Median PFS for patients with stage II/III and no residual disease was 35.9, 38.8, and 35.5 months, respectively. Median overall survival for all enrolled was 75.5, 78.9, and 72.9 months, respectively, and median overall survival for stage II/III with no gross residual disease was 98.8 months, 104.8 months, and not reached. Mean patient-reported Functional Assessment of Cancer Therapy neurotoxicity scores (Gynecologic Oncology Group) were similar for all arms, but the mean Trial Outcome Index of the Functional Assessment of Cancer Therapy–Ovary scores during chemotherapy were statistically worse in the IP cisplatin arm. CONCLUSION Compared with the IV carboplatin reference arm, the duration of PFS was not significantly increased with either IP regimen when combined with bevacizumab and was better tolerated than IP cisplatin.

Phase I Trial of Bortezomib and Carboplatin in Recurrent Ovarian or Primary Peritoneal Cancer

2005 ◽  
Vol 23 (25) ◽  
pp. 5943-5949 ◽  
Author(s):  
C. Aghajanian ◽  
D.S. Dizon ◽  
P. Sabbatini ◽  
J.J. Raizer ◽  
J. Dupont ◽  
...  
Keyword(s):  
Cancer Therapy ◽  
Functional Assessment ◽  
Gynecologic Oncology ◽  
Maximum Tolerated Dose ◽  
Fixed Dose ◽  
Wall Thickening ◽  
Gynecologic Oncology Group ◽  
Oncology Group ◽  
Peritoneal Cancer ◽  
Dose Reductions

PurposeTo determine the maximum-tolerated dose, pharmacodynamics, and safety of the combination of bortezomib and carboplatin in recurrent ovarian cancer.Patients and MethodsFifteen patients were treated with a fixed dose of carboplatin (area under the curve [AUC] 5) and increasing doses of bortezomib (0.75, 1, 1.3, and 1.5 mg/m2/dose). Patients must have received upfront chemotherapy and up to two prior chemotherapy regimens for recurrent disease. Neurologic evaluation was performed at baseline and after every two cycles by the Functional Assessment of Cancer Therapy/Gynecologic Oncology Group neurotoxicity questionnaire and examination by an attending neurologist. All patients received carboplatin alone in cycle 1 to establish baseline pharmacodynamics for nuclear factor-kappa B (NF-kB). Starting with cycle 2, patients were treated with carboplatin on day 1 and bortezomib on days 1, 4, 8, and 11.ResultsDiarrhea, rash, neuropathy, and constipation (with colonic wall thickening on computed tomography) were dose-limiting toxicities, occurring in the two patients treated at the 1.5 mg/m2/dose level. The Functional Assessment of Cancer Therapy/Gynecologic Oncology Group neurotoxicity questionnaire was helpful in guiding the need for dose reductions. Neurotoxicity was manageable through six cycles, with appropriate dose reductions. Carboplatin had no effect on bortezomib pharmacodynamics as measured by percent inhibition of the 20S proteasome. Bortezomib decreased carboplatin-induced NF-kB. The overall response rate to this combination was 47%, with two complete responses (CR) and five partial responses, including one CR in a patient with platinum-resistant disease.ConclusionThe recommended phase II dose of bortezomib administered in combination with carboplatin (AUC 5) is 1.3 mg/m2/dose.

Psychometric evaluation of the Functional Assessment of Cancer Therapy/Gynecologic Oncology Group—Neurotoxicity (Fact/GOG-Ntx) questionnaire for patients receiving systemic chemotherapy

2003 ◽  
Vol 13 (6) ◽  
pp. 741-748 ◽  
Author(s):  
E. A. Calhoun ◽  
E. E. Welshman ◽  
C.-H. Chang ◽  
J. R. Lurain ◽  
D. A. Fishman ◽  
...  
Keyword(s):  
Quality Of Life ◽  
Ovarian Cancer ◽  
Cancer Therapy ◽  
Functional Assessment ◽  
Gynecologic Oncology ◽  
Psychometric Evaluation ◽  
Gynecologic Oncology Group ◽  
Oncology Group ◽  
The Impact

The purpose of this study was to validate the Functional Assessment of Cancer Therapy/Gynecologic Oncology Group—Neurotoxicity (FACT/GOG-Ntx) questionnaire. The FACT/GOG-Ntx is the FACT-G plus an eleven-item subscale (Ntx subscale) that evaluates symptoms and concerns associated specifically with chemotherapy-induced neuropathy. Two groups of women with ovarian cancer completed the FACT/GOG-Ntx: one group with known neurotoxicities and one group of chemotherapy-naive women newly diagnosed with ovarian cancer. Levels of patient neuropathy, severity of toxicity, and patient quality of life from diagnosis of ovarian cancer to 12 months post-diagnosis were assessed. The Ntx subscale significantly differentiated the two groups at baseline and 3- and 6-month follow-ups, demonstrating significantly fewer problems among chemotherapy-naive patients than among patients with known neuropathy. The FACT/GOG-Ntx is a reliable and valid instrument for assessing the impact of neuropathy on health-related quality of life. The Ntx subscale demonstrated sensitivity to meaningful clinical distinctions and change over time.

scholarly journals Efficacy of obesity in metastatic colorectal cancer patients treated with bevacizumab-based chemotherapy combinations: A Turkish Oncology Group Study

2016 ◽  
Vol 27 ◽  
pp. vi176
Author(s):  
M. Artac ◽  
L. Korkmaz ◽  
H. Coskun ◽  
F. Dane ◽  
B. Karabulut ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Metastatic Colorectal Cancer ◽  
Cancer Patients ◽  
Oncology Group ◽  
Oncology Group Study ◽  
Colorectal Cancer Patients
Sign in / Sign up

Export Citation Format

Share Document